Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Evacetrapib in Dyslipidemia
NCT02168803Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of evacetrapib in dyslipidemia (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve, Maximum Concentration and 1 more. Started May 2014; status: completed.
02
Drugs
evacetrapib
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02168803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168803.